Bellerophon Therapeutics Crescita futura

Future criteri di controllo 0/6

Al momento non disponiamo di una copertura analitica sufficiente per prevedere la crescita e il fatturato di Bellerophon Therapeutics.

Informazioni chiave

n/a

Tasso di crescita degli utili

n/a

Tasso di crescita dell'EPS

Biotechs crescita degli utili	28.3%
Tasso di crescita dei ricavi	n/a
Rendimento futuro del capitale proprio	n/a
Copertura analitica	None
Ultimo aggiornamento	n/a

Aggiornamenti recenti sulla crescita futura

Recent updates

Is Bellerophon Therapeutics (NASDAQ:BLPH) In A Good Position To Invest In Growth?

Jan 18

Bellerophon Therapeutics EPS misses by $0.01

Nov 05

In questa sezione di solito presentiamo le proiezioni di crescita dei ricavi e degli utili basate sulle stime di consenso degli analisti professionisti per aiutare gli investitori a capire la capacità della società di generare profitti. Tuttavia, poiché Bellerophon Therapeutics non ha fornito dati sufficienti sul passato e non ha previsioni degli analisti, i suoi utili futuri non possono essere calcolati in modo affidabile estrapolando i dati passati o utilizzando le previsioni degli analisti.

Si tratta di una situazione piuttosto rara, dato che il 97% delle società coperte da SimplyWall St dispone di dati finanziari passati.

Previsioni di crescita degli utili e dei ricavi

OTCPK:BLPH - Stime future degli analisti e dati finanziari passati (USD Millions )
Data	Ricavi	Guadagni	Flusso di cassa libero	Liquidità dell'operazione	Avg. Numero di analisti
9/30/2023	6	-9	-12	-12	N/A
6/30/2023	6	-12	-11	-11	N/A
3/31/2023	6	-11	-10	-10	N/A
12/31/2022	N/A	-20	-18	-18	N/A
9/30/2022	N/A	-19	-17	-17	N/A
6/30/2022	N/A	-19	-18	-18	N/A
3/31/2022	N/A	-18	-20	-20	N/A
12/31/2021	N/A	-18	-23	-23	N/A
9/30/2021	N/A	-21	-25	-25	N/A
6/30/2021	N/A	-25	-25	-25	N/A
3/31/2021	N/A	-25	-23	-23	N/A
12/31/2020	N/A	-25	-20	-20	N/A
9/30/2020	N/A	-21	-16	-16	N/A
6/30/2020	N/A	-17	-15	-15	N/A
3/31/2020	N/A	-17	-15	-15	N/A
12/31/2019	N/A	-13	-13	-13	N/A
9/30/2019	N/A	-10	-14	-14	N/A
6/30/2019	N/A	5	-16	-16	N/A
3/31/2019	N/A	-2	-17	-17	N/A
12/31/2018	N/A	3	-15	-15	N/A
9/30/2018	N/A	-20	-16	-16	N/A
6/30/2018	N/A	-39	-14	-14	N/A
3/31/2018	N/A	-32	-13	-13	N/A
12/31/2017	N/A	-55	-16	-16	N/A
9/30/2017	N/A	-38	-14	-14	N/A
6/30/2017	N/A	-35	N/A	-14	N/A
3/31/2017	N/A	-36	N/A	-14	N/A
12/31/2016	N/A	-24	N/A	-17	N/A
9/30/2016	N/A	-27	N/A	-32	N/A
6/30/2016	N/A	-34	N/A	-40	N/A
3/31/2016	N/A	-41	N/A	-44	N/A
12/31/2015	N/A	-46	N/A	-46	N/A
9/30/2015	N/A	-48	N/A	-41	N/A
6/30/2015	N/A	-53	N/A	-45	N/A
3/31/2015	N/A	-58	N/A	-49	N/A
12/31/2014	N/A	-60	N/A	-71	N/A
9/30/2014	N/A	-64	N/A	-71	N/A
3/31/2014	N/A	-62	N/A	-72	N/A

Previsioni di crescita futura degli analisti

Guadagni vs tasso di risparmio: Dati insufficienti per determinare se la crescita degli utili prevista BLPH è superiore al tasso di risparmio ( 2.6% ).

Guadagni vs Mercato: Dati insufficienti per determinare se si prevede che gli utili di BLPH cresceranno più velocemente del mercato US

Guadagni ad alta crescita: Dati insufficienti per determinare se si prevede che gli utili di BLPH cresceranno in modo significativo nei prossimi 3 anni.

Ricavi vs Mercato: Dati insufficienti per determinare se si prevede che i ricavi di BLPH cresceranno più rapidamente del mercato US.

Ricavi ad alta crescita: Dati insufficienti per determinare se si prevede che i ricavi di BLPH cresceranno più rapidamente di 20% all'anno.

Previsioni di crescita dell'utile per azione

Rendimento futuro del capitale proprio

ROE futuro: Dati insufficienti per determinare se il Return on Equity di BLPH è previsto essere elevato tra 3 anni

Bellerophon Therapeutics Crescita futura

Future criteri di controllo 0/6

Informazioni chiave

Aggiornamenti recenti sulla crescita futura

Consensus EPS estimates fall by 21%

Price target decreased by 8.0% to US$25.75

Consensus revenue estimates increase by 157%

Consensus revenue estimates fall by 20%

Forecast to breakeven in 2025

Price target decreased to US$24.50

Recent updates

Bellerophon Therapeutics, Inc. Files Form 15

Bellerophon Therapeutics, Inc. Announces Executive Changes

Bellerophon Therapeutics, Inc. Announces Resignation of Theodore Wang as a Member of the Company's Board

New major risk - Share price stability

New major risk - Financial position

New major risk - Revenue and earnings growth

Bellerophon Therapeutics to Be Delisted from the Nasdaq Capital Market At Opening of Business on July 28, 2023 Unless It Timely Requests A Hearing Before Nasdaq Hearings Panel to Address Deficiencies and Present Plan to Regain Compliance

Bellerophon Therapeutics, Inc. Announces Resignation of Crispin Teufel as Board of Director

New major risk - Financial position

New major risk - Market cap size

Consensus EPS estimates fall by 21%

Bellerophon Therapeutics, Inc. Announces Top-Line Data from Phase 3 REBUILD Clinical Trial of INOpulse® for Treatment of Fibrotic Interstitial Lung Disease

Price target decreased by 8.0% to US$25.75

Insider recently sold US$82k worth of stock

Consensus revenue estimates increase by 157%

Bellerophon Therapeutics, Inc. Announces Last Patient Has Completed Blinded Treatment in Phase 3 REBUILD Study for INOpulse® in Fibrotic Interstitial Lung Disease

Consensus revenue estimates fall by 20%

Forecast to breakeven in 2025

Bellerophon Therapeutics, Inc. Receives IND Clearance from China NMPA to Conduct Phase 3 Clinical Trial in China for INOpulse(R) in Fibrotic Interstitial Lung Disease

Bellerophon Therapeutics, Inc. Announces Completion of Enrollment in Phase 3 REBUILD Study for INOpulse® in Fibrotic Interstitial Lung Disease

Bellerophon Therapeutics (NASDAQ:BLPH) Will Have To Spend Its Cash Wisely

Price target decreased to US$24.50

Insufficient new directors

Bellerophon Provides Clinical Program Update

Bellerophon Announces FDA Acceptance of Change to Ongoing Phase 3 Rebuild Study of Inopulse for Treatment of Fibrotic Interstitial Lung Disease

Bellerophon stock gains ~24% after getting FDA nod to reduce phase 3 study size

Bellerophon Therapeutics GAAP EPS of -$0.43 beats by $0.17

Bellerophon Therapeutics, Inc. Announces New Board Appointment

Price target decreased to US$24.50

Insufficient new directors

Bellerophon Therapeutics, Inc., Annual General Meeting, Jun 01, 2022

Insufficient new directors

Is Bellerophon Therapeutics (NASDAQ:BLPH) In A Good Position To Invest In Growth?

Bellerophon Therapeutics, Inc. Reports Positive Top-Line Data from Phase 2 Acute Dose Escalation Study of Inopulse® for Treatment of Pulmonary Hypertension Associated with Sarcoidosis

CFO & Secretary Assaf Korner has left the company

Price target decreased to US$25.00

Bellerophon Therapeutics, Inc. Provides Clinical Program Update

Bellerophon Therapeutics, Inc.(NasdaqCM:BLPH) dropped from Russell 3000E Index

Bellerophon Therapeutics, Inc. Provides Clinical Program Update

Bellerophon Therapeutics Announces First Patient Enrolled in Phase 3 REBUILD Study Evaluating INOpulse® for the Treatment of Fibrotic Interstitial Lung Disease

Bellerophon Therapeutics, Inc. Announces Results of Interim Analysis of Phase 3 COViNOX Study of INOpulse for the Treatment of COVID-19

Bellerophon Therapeutics EPS misses by $0.01

Previsioni di crescita degli utili e dei ricavi

Previsioni di crescita futura degli analisti

Previsioni di crescita dell'utile per azione

Rendimento futuro del capitale proprio

Scoprire le aziende in crescita